STELIOS THERAPEUTICS
Stelios Therapeutics is an early-stage company developing novel AAV-based gene therapies for rare genetic cardiac conditions. The company is founded based on research conducted at the University of California San Diego (UCSD) by a distinguished team of researchers and scientists with extensive experience and expertise in gene therapy drug development.
STELIOS THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2017-01-01
Address:
Cardiff By The Sea, California, United States
Country:
United States
Status:
Active
Similar Organizations
Affini-T Therapeutics
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Employees Featured
Founder
More informations about "Stelios Therapeutics"
PharmaShots | Incisive News in 3 Shots
Stelios Therapeutics is an early-stage company developing novel AAV-based gene therapies for rare genetic cardiac conditions. The company is founded based on research conducted at the …See details»
Stelios Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore Stelios Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, , Technology Platform:Gene therapy, Drug:LX-2021.See details»
LX-2021 - Drug Targets, Indications, Patents - Synapse - Patsnap
LX-2021: a GJA1 agonists Drug, Initially developed by Stelios Therapeutics, Inc., Now, its global highest R&D status is Preclinical, Mechanism: GJA1 agonists(Gap ...See details»
LX-2020 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 LX-2020: a PKP2 gene stimulants, Gene transference Drug, Initially developed by Stelios Therapeutics, Inc., Now, its global highest R&D status is Phase 1/2, Mechanism: PKP2 …See details»
Lexeo snaps up Stelios, bolstering pipeline with trio of rare heart ...
Jul 21, 2021 As Lexeo Therapeutics ushers two gene therapies toward the clinic, the company is adding another three heart disease programs to its already busy pipeline.See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy …
Jul 21, 2021 Stelios Therapeutics is an early-stage company developing novel AAV-based gene therapies for rare genetic cardiac conditions. The company is founded based on research conducted at the University of California San …See details»
LEXEO Therapeutics acquires Stelios Therapeutics - 2021-07-21 ...
Jul 21, 2021 Stelios Therapeutics Stelios Therapeutics is an early-stage company developing novel AAV-based gene therapies for rare genetic cardiac conditions.See details»
Stelios Therapeutics, Inc. - Company Profile - Corporation Wiki
May 10, 2017 View company leaders and background information for Stelios Therapeutics, Inc. Search our database of over 100 million company and executive profiles.See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with ...
Jul 21, 2021 LEXEO Therapeutics today announced that it has acquired Stelios Therapeutics, an early-stage company developing novel adeno-associated virus (AAV)-mediated gene …See details»
Lexeo Acquires Stelios to Expand Pipeline into Rare Cardiac Gene ...
Jul 21, 2021 Clinical stage gene therapy biotech Lexeo Therapeutics has acquired Stelios Therapeutics, an early-stage company developing novel adeno-associated virus-mediated …See details»
Stelios Therapeutics - CB Insights
Stelios Therapeutics develops novel adeno-associated virus-mediated gene therapies for rare genetic cardiac conditions. On July 21st, 2021, Stelios Therapeutics was acquired by LEXEO …See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with ...
Jul 21, 2021 The Stelios programs complement and broaden LEXEO’s advanced pre-clinical gene therapy pipeline in rare cardiac diseases, which currently includes LX2006, an IV …See details»
Stelios Therapeutics: Drug pipelines, Patents, Clinical trials - Synapse
Explore Stelios Therapeutics with its drug pipeline, therapeutic area, technology platform, .See details»
Lexeo snaps up Stelios, bolstering pipeline with trio of rare heart ...
Jul 28, 2021 As Lexeo Therapeutics ushers two gene therapies toward the clinic, the company is adding another three heart disease programs to its already busy pipeline. The assets come …See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with ...
Jul 22, 2021 LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, announced that it has acquired …See details»
Stelios Therapeutics Acquired - San Diego Business Journal
Jul 20, 2021 Stelios Therapeutics is an early-stage company developing novel adeno-associated virus (AAV)-based gene therapies for rare genetic cardiac conditions. The local biotech, …See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline
Jul 21, 2021 The Stelios programs complement and broaden LEXEO’s advanced pre-clinical gene therapy pipeline in rare cardiac diseases, which currently includes LX2006, an IV …See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with ...
Jul 28, 2021 LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, today announced that it has …See details»
Lexeo keeps foot on the gas pedal with $100M financing to follow …
Sep 9, 2021 The series B fundraising comes barely two months after Lexeo snapped up three heart disease programs through the acquisition of Stelios Therapeutics.See details»